Roel van Kampen

Suspicion-based screening for occult malignancy in lower-extremity venous thrombosis: a real-world cohort study

Yael Appelboom, Inge H.Y. Luu, Aukje Swillens, Eveline van den Bos et autres

nl (code pays fourni par la source)

Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first‐line therapy irrespective of frailty levels

Wassilis S.C. Bruins, Febe Smits, Carolien Duetz, Kazem Nasserinejad et autres

Abstract The treatment landscape for older patients with multiple myeloma (MM) has rapidly evolved with the introduction of CD38‐targeting antibodies. Yet, outcomes remain highly variable and are only partially explained by frailty status. To address this, we investigated the impact of the …

nl (code pays fourni par la source)

T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells

Jaco A. C. van Bruggen, Fleur S. Peters, Morris Mes, Joanne M. Rietveld et autres

ABSTRACT: Autologous T-cell-based therapies, such as chimeric antigen receptor (CAR) T-cell therapy, exhibit low success rates in chronic lymphocytic leukemia (CLL) and correlate with a dysfunctional T-cell phenotype observed in patients. Despite various proposed mechanisms of T-cell dysfunction in CLL, the specific …

nl, us (code pays fourni par la source)

The evolving landscape of COVID ‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC , the European research initiative on CLL

Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfò, Anargyros Kapetanakis et autres

In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from …

it, gr, gb, es, ch, rs, se, be, cz, de, us, Égypte, ar, dk, pt, il, hr, ru, pl, nl, in, ro, np (code pays fourni par la source)

P-116 The simplified frailty index (S-FI) identifies a less vulnerable population of frail patients than patients who are defined frail using the International Myeloma working Group Frailty index (IMWG-FI)

Kaz Groen, Febe Smits, Kazem Nasserinejad, Mark‐David Levin et autres

Gene expression responses reflecting 5-FU-induced toxicity: Comparison between patient colon tissue and 3D human colon organoids

Daniela Rodrigues, Roel van Kampen, Ad A. van Bodegraven, Jos C. S. Kleinjans et autres

Capecitabine is a chemotherapeutic drug that is widely used as a monotherapy option in advanced cancer patients. After administration, it is converted into its active metabolite 5-fluorouracil (5-FU), a cytotoxic compound that may also induce adverse side effects in the gastrointestinal (GI) …

nl (code pays fourni par la source)

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Thomas Chatzikonstantinou, Anargyros Kapetanakis, Lydia Scarfò, Georgios Karakatsoulis et autres

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. …

gr, it, gb, es, ch, rs, se, be, cz, de, Égypte, ar, dk, pt, il, hr, ru, pl, nl, in, ro, np (code pays fourni par la source)

Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL

Marco Vincent Haselager, Rachel Thijssen, Christopher M. West, Louise Young et autres

In chronic lymphocytic leukemia (CLL), the lymph node (LN) microenvironment delivers critical survival signals by inducing the expression of anti-apoptotic Bcl-2 members Bcl-XL, Bfl-1, and Mcl-1, resulting in apoptosis blockade. We determined previously that resistance against various drugs, among which is the …

nl, gb, ca (code pays fourni par la source)

Direct Oral Anticoagulants: Drug Selection by Means of the SOJA Method

Robert Janknegt, Roel van Kampen, Niels W. Boone, Renée C.R.M. Vossen

Direct acting anticoagulant drugs [DOACs], consisting of apixaban, dabigatran, edoxaban and rivaroxaban have been available for various indications for 3year [edoxaban] up to over a decade [dabigatran and rivaroxaban]. These medicines have shown good clinical efficacy and are usually well tolerated compared …

us, nl (code pays fourni par la source)

Direct Oral Anticoagulants: Drug Selection by Means of the SOJA Method

Robert Janknegt, Roel van Kampen, Niels W. Boone, Renée C.R.M. Vossen

MethodsThe SOJA method is a model for rational drug selection.The relevant selection criteria for a certain group of drugs are defined and judged by a panel of experts [i.e. the authors of the present article].The more important a selection criterion is considered, …

us, nl (code pays fourni par la source)

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells

Anne W. J. Martens, Susanne R. Janssen, Ingrid A. M. Derks, Homer Adams et autres

Background Bispecific antibodies are promising new therapeutics in B cell malignancies. Whether they lead to potent T cell activation despite described T cell dysfunction in chronic lymphocytic leukemia (CLL), and are able to effectively target high-risk or venetoclax-resistant samples, is currently unknown. …

nl, us (code pays fourni par la source)

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition

Janet R. Vos, Ingrid E. Fakkert, Joanne A. de Hullu, Anne M. van Altena et autres

BACKGROUND: Women with epithelial ovarian cancer (OC) have a higher chance to benefit from poly (ADP-ribose) polymerase inhibitor (PARPi) therapy if their tumor has a somatic or hereditary BRCA1/2 pathogenic variant. Current guidelines advise BRCA1/2 genetic predisposition testing for all OC patients, …

nl (code pays fourni par la source)